Alibaba Health

Alibaba Health, also known as AliHealth, is a Chinese healthcare company listed on the Hong Kong Stock Exchange and associated with Alibaba Group. Its principal corporate vehicle is Alibaba Health Information Technology Limited, while Alibaba Health is used as the public-facing name for Alibaba’s healthcare activities. The business focuses on digital health services and resources, with activities spanning pharmaceutical e-commerce, online healthcare, consumer healthcare and technology-enabled services for healthcare organizations. The company’s origins are connected to the listed Hong Kong retail company Shui Hing and the corporate succession that followed its sale, renaming and acquisition. In 2000, CITIC Group acquired the business then known as Easy Concepts and later renamed it CITIC 21CN. Alibaba and Yunfeng Capital acquired a controlling stake in CITIC 21CN in January 2014. The company was subsequently renamed Alibaba Health, creating a listed platform through which Alibaba could develop healthcare-related businesses. Alibaba said the target’s drug-data capabilities were relevant to its expansion into healthcare. Alibaba Health’s consumer-facing activities include online transactions involving medicines, medical devices and health products, together with healthcare information and service connections. Its online healthcare activities can connect users with healthcare resources, while its broader digital-health work supports healthcare-sector participants and operational processes. The exact mix of offerings can change with partnerships, regulation and Alibaba Group’s strategy. Pharmaceutical and medical activities are subject to requirements concerning product authorization, online medicine sales, prescriptions, professional practice, advertising, data use and platform operations. The company has also used acquisitions, investments and internal transfers to expand beyond a narrow online-pharmacy model. A proposed 2015 transfer of Alibaba’s online pharmacy operations from Tmall did not proceed after regulatory uncertainty affected the transaction. In 2018, Alibaba announced a new transfer of certain healthcare categories on Tmall to Alibaba Health. During the same period, Alibaba Health invested in several offline healthcare businesses, including Guizhou Ensure, ShuYu Civilian Pharmacy Corporation and Huaren Health, in an effort to develop more stable sources of cash flow. During the COVID-19 pandemic, the company reported stronger revenue from direct sales and recorded its first profitable year after reporting net losses since inception, according to the referenced account. In November 2023, it announced a proposed acquisition from Taobao involving AJK Technology Holding Ltd. The transaction was described as providing access to certain services connected with Alibaba’s marketing tools, with the stated objective of improving profitability. Alibaba Health therefore combines a listed-company structure with Alibaba ecosystem links in commerce, technology, payments and logistics, while operating in a highly regulated Chinese healthcare market.

Alibaba Health’s corporate history begins with Shui Hing, a Hong Kong retail company listed on the Hong Kong Stock Exchange in 1971. In 1998, Shui Hing was sold to fashion retailer Easyknit International Holdings and renamed Easy Concepts. CITIC Group acquired Easy Concepts in 2000, after which the business became associated with the CITIC 21CN name. The decisive change came in January 2014, when Alibaba and Yunfeng Capital acquired a controlling stake in CITIC 21CN. The transaction gave Alibaba an established listed vehicle through which it could develop healthcare activities. Contemporary speculation suggested that the deal might have been intended as a reverse takeover that could facilitate an Alibaba listing in Hong Kong, but accounts cited in the reference material state that Alibaba denied this purpose. Alibaba instead emphasized CITIC 21CN’s drug-data platform and its relevance to expansion in healthcare. The company was subsequently renamed Alibaba Health. Alibaba Health’s early strategic development involved attempts to combine Alibaba’s online commerce infrastructure with pharmaceutical and healthcare capabilities. In 2015, Alibaba agreed to transfer its online pharmacy operations from Tmall to Alibaba Health in exchange for newly issued shares and convertible bonds. The arrangement ultimately lapsed because of regulatory uncertainty surrounding online drug sales. The episode demonstrated the importance of China’s regulatory framework to the structure and timing of the company’s business expansion. In May 2018, Alibaba announced another transfer involving several healthcare categories on Tmall. Alibaba Health also made investments in offline healthcare companies during 2018, including Guizhou Ensure, ShuYu Civilian Pharmacy Corporation and Huaren Health. These investments reflected an effort to diversify beyond online activity, build relationships with physical healthcare and pharmacy businesses, and develop more dependable cash flows. The company had reported losses for multiple years, making profitability and business-model diversification important strategic concerns. The company’s business has since been described across several connected areas: pharmaceutical e-commerce, online healthcare, consumer healthcare and digital solutions for the healthcare sector. It operates through relationships with consumers, medicine and health-product suppliers, pharmacies, healthcare providers, pharmaceutical companies and other partners. Its role is not limited to selling products; it also uses digital platforms to provide information, facilitate access to healthcare resources and support industry processes. The scope and organization of individual services may change as regulations and Alibaba Group priorities evolve. The COVID-19 period brought increased revenue from direct sales, and Alibaba Health reported its first profitable year after recording net losses since inception. The pandemic highlighted the importance of online access to medicines and health products, while also increasing attention on compliance, fulfillment, medical claims and data governance. In November 2023, Alibaba Health stated that it would acquire AJK Technology Holding Ltd from Taobao. The proposed transaction was described as giving Alibaba Health access to certain services associated with Alibaba’s marketing tools, with the aim of improving profitability. This move illustrated the continuing connection between Alibaba Health and the wider Alibaba commercial technology ecosystem. Today, Alibaba Health remains a Hong Kong-listed healthcare platform focused primarily on China, operating at the intersection of digital commerce, medicine retail, online healthcare and healthcare-sector technology. Its activities remain subject to rules governing medicines, medical services, prescriptions, data and online platforms.

• 2023

  AJK Technology acquisition announced

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  Alibaba Health announced a proposed acquisition of AJK Technology Holding Ltd from Taobao to obtain certain marketing-tool services and support profitability.

• 2018

  Healthcare categories and offline investments expand

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  Alibaba announced a transfer of selected Tmall healthcare categories to Alibaba Health, while Alibaba Health invested in several offline healthcare businesses.

• 2015

  Online pharmacy transfer proposal lapses

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  A proposed transfer of Alibaba’s Tmall online pharmacy operations to Alibaba Health did not proceed because of regulatory uncertainty.

• 2014

  Alibaba and Yunfeng Capital acquire control

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  Alibaba and Yunfeng Capital acquired a controlling stake in CITIC 21CN, which was subsequently renamed Alibaba Health.

• 2000

  CITIC Group acquires Easy Concepts

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  CITIC Group acquired Easy Concepts, which was later renamed CITIC 21CN.

• 1998

  Shui Hing becomes Easy Concepts

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  After being sold to Easyknit International Holdings, Shui Hing was renamed Easy Concepts.

• 1971

  Shui Hing is listed in Hong Kong

  [1]Alibaba Health - Wikipediaen.wikipedia.org

  The corporate lineage that later led to Alibaba Health can be traced to Shui Hing, a Hong Kong retail company listed on the Hong Kong Stock Exchange.

A digital healthcare platform connecting consumers, medicines, healthcare resources and industry participants through Alibaba-related technology and commerce capabilities.

• Digital commerce

  Pharmaceutical e-commerce

  Alibaba Health’s pharmaceutical e-commerce activities connect consumers with medicines, medical devices and health products through online channels. The business can include product discovery, information, transaction facilitation and related fulfillment or platform services. Product availability and transaction processes depend on supplier qualifications, applicable medicine rules and the regulatory treatment of online sales.

• Digital healthcare services

  Online healthcare

  Online healthcare uses digital interfaces to provide healthcare information, consultation-related services or connections between users and healthcare resources. Depending on the specific service, this may involve providers, pharmacies or other healthcare partners. Delivery is constrained by rules concerning medical practice, prescriptions, professional responsibility and health-data handling.

• Consumer health

  Consumer healthcare

  Consumer healthcare covers selected health and medical-consumption scenarios for individuals. Alibaba Health can use online channels to present services, products and provider information and to connect consumers with participating organizations. The precise scope differs by market, partner and regulatory requirements.

• Healthcare technology

  Digital healthcare solutions

  Alibaba Health’s healthcare-technology activities support digitalization across parts of the healthcare industry. They may involve platforms, data capabilities, operational tools or other technology-enabled services for healthcare participants. The company’s original connection to drug-data capabilities and its relationship with Alibaba’s technology ecosystem are central elements of this positioning.

• 2024

  Alibaba Health Pharmacy Repeatedly Fined for Illegal Advertising, False Promotion

  In 2024, Alibaba Health Pharmacy was fined RMB 450,000 by the Guangzhou Huangpu District Market Supervision Administration for publishing advertisements for drugs, health foods, and medical devices without review and for falsely promoting therapeutic functions; in 2025, it was fined another RMB 280,000 for advertisements that were not reviewed and contained false and pornographic content. Compliance of the platform's self-operated advertising is being questioned.

  Source

• 2021

  China fines Alibaba Health for unreported acquisition

  China's State Administration for Market Regulation fined Alibaba Health RMB 500,000 for implementing a concentration by acquiring a 25% stake in Guizhou Yishu without making the required prior filing. The regulator said the transaction had no effect of eliminating or restricting competition.

  Source

Read more

• 2023

  Proposed acquisition of AJK Technology HoldingM&A

  Background

  Alibaba Health sought additional tools and capabilities that could support profitability within the Alibaba ecosystem.

  Action taken

  Alibaba Health stated that it would acquire AJK Technology Holding Ltd from Taobao.

  Aftermath

  The proposed deal was described as providing certain Alibaba marketing-tool services; the referenced material does not establish its final completion status.

  Reported acquisition consideration. US$1.73 billion (November 2023 announcement)

  Source

• 2018

  Transfer of selected Tmall healthcare categoriesStrategy

  Background

  Alibaba continued to reorganize healthcare-related commerce within its corporate ecosystem after the earlier online-pharmacy proposal lapsed.

  Action taken

  Alibaba announced that several healthcare categories on Tmall would be transferred to Alibaba Health.

  Aftermath

  The transfer strengthened Alibaba Health’s role in Alibaba’s healthcare commerce activities.

  Reported transaction consideration. US$1.35 billion (May 2018 announcement)

  Source

• 2018

  Investments in offline healthcare businessesM&A

  Background

  Alibaba Health had experienced losses and sought to broaden its business base and develop more stable cash flows.

  Action taken

  Alibaba Health invested in Guizhou Ensure, ShuYu Civilian Pharmacy Corporation and Huaren Health.

  Aftermath

  The investments expanded the company’s links with offline healthcare and pharmacy businesses.

  Source

• 2015

  Proposed transfer of Tmall online pharmacy operationsStrategy

  Background

  Alibaba attempted to consolidate its online pharmacy operations within Alibaba Health as part of its healthcare expansion.

  Action taken

  Alibaba agreed to transfer the operations from Tmall in exchange for newly issued Alibaba Health shares and convertible bonds.

  Aftermath

  Alibaba Health allowed the arrangement to lapse because regulatory uncertainty made the online drug-sales structure difficult to complete.

  Proposed consideration. US$2.5 billion in newly issued shares and convertible bonds (2015 proposal)

  Source

• 2014

  Acquisition of controlling stake in CITIC 21CNM&A

  Background

  Alibaba sought to expand into healthcare and identified CITIC 21CN’s drug-data platform as strategically relevant.

  Action taken

  Alibaba and Yunfeng Capital acquired a controlling stake in CITIC 21CN, which was later renamed Alibaba Health.

  Aftermath

  The transaction established the listed corporate platform that became Alibaba’s healthcare unit.

  Reported acquisition consideration. US$170 million (January 2014 transaction)

  Source

• 2021.11.20

  Reported2021.11.20

  China fines Alibaba Health for unreported acquisition[6]China fines Alibaba Health for unreported acquisitionfinance.ce.cn

  China's State Administration for Market Regulation fined Alibaba Health RMB 500,000 for implementing a concentration by acquiring a 25% stake in Guizhou Yishu without making the required prior filing. The regulator said the transaction had no effect of eliminating or restricting competition.

• 2021.10.14

  Alibaba Health and Eisai China sign strategic partnership[7]阿里健康与卫材中国签署战略合作协议news.pedaily.cn

  Alibaba Health and Eisai China signed a strategic cooperation agreement to work together on internet healthcare businesses in neurology, digestive diseases and oncology, with further cooperation planned on innovative project technologies.

• 2021.04.08

  Reported2021.04.08

  Alibaba Health completes joint investment in Yingsheng Bio[8]阿里健康完成对英盛生物的联合投资finance.sina.com.cn

  Alibaba Health announced that it had completed a joint investment in clinical mass spectrometry company Yingsheng Bio.

• 2020.05.19

  Reported2020.05.19

  Ali Health launches Famous Doctors Channel[9]阿里健康上线名医频道finance.sina.com.cn

  Ali Health launched the Famous Doctors Channel, offering services including livestreams and access through the Alipay app.

• 2020.04.21

  Reported2020.04.21

  Ali Health launches online COVID-19 nucleic acid test booking[10]阿里健康推出新冠核酸检测在线预约服务finance.sina.com.cn

  Ali Health, together with the named health-service stores, launched online booking for COVID-19 nucleic acid testing in 10 Chinese cities from April 21; residents could book through Taobao or Tmall, with electronic reports available as quickly as one day later.

• 2020.04.21

  Reported2020.04.22

  Alibaba Health launched online COVID-19 test booking in 10 Chinese cities[11]阿里健康在中国10个城市推出新冠核酸检测在线预约服务finance.sina.com.cn

  Alibaba Health launched an online appointment service for COVID-19 nucleic acid testing in 10 Chinese cities; residents could book through Taobao or Tmall, with electronic reports available as quickly as one day later.

• 2020.02.13

  Reported2020.02.14

  Alibaba Health launches Hubei medicine registration service[12]阿里健康上线湖北缺药登记服务tech.sina.com.cn

  Alibaba Health launched a medicine-shortage registration service for chronic-disease patients in Hubei, allowing patients to submit information about urgently needed medicines so the service could seek supplies.

• 2020.02.06

  Reported2020.02.09

  Alibaba Health agrees to acquire Ali JK ZNS[13]阿里健康拟收购Ali JK ZNS全部股权finance.sina.com.cn

  Alibaba Health entered into a share purchase agreement to acquire all equity in Ali JK ZNS Limited for HK$8.075 billion, payable through the issue of 860 million consideration shares at completion.

Read more

1. 1Alibaba Health - Wikipediaen.wikipedia.org
2. 2Alibaba Health official websitealibabahealth.com
3. 3Alibaba Health Pharmacy Repeatedly Fined for Illegal Advertising, False Promotionjiemian.com
4. 4Alibaba Health Pharmacy Repeatedly Fined for Illegal Advertising, False Promotionccn.com.cn
5. 5Alibaba Health Pharmacy Repeatedly Fined for Illegal Advertising, False Promotionfinance.sina.com.cn
6. 6China fines Alibaba Health for unreported acquisitionfinance.ce.cn
7. 7阿里健康与卫材中国签署战略合作协议news.pedaily.cn
8. 8阿里健康完成对英盛生物的联合投资finance.sina.com.cn
9. 9阿里健康上线名医频道finance.sina.com.cn
10. 10阿里健康推出新冠核酸检测在线预约服务finance.sina.com.cn
11. 11阿里健康在中国10个城市推出新冠核酸检测在线预约服务finance.sina.com.cn
12. 12阿里健康上线湖北缺药登记服务tech.sina.com.cn
13. 13阿里健康拟收购Ali JK ZNS全部股权finance.sina.com.cn
14. 1480亿港元收购天猫医疗电商业务 阿里健康整合提速tech.sina.com.cn
15. 15阿里健康(00241)收购医药核心资产，顺势加码互联网医疗finance.sina.com.cn
16. 16阿里健康80.75亿收购天猫平台上销售药品等相关业务finance.ce.cn
17. 17阿里健康80.75亿收购天猫平台上销售药品等相关业务finance.sina.com.cn
18. 18阿里健康81亿港元收购大股东资产 涉逾530名天猫商家finance.sina.com.cn
19. 19阿里健康完成对英盛生物联合投资，向精准医疗“前沿阵地”再挺进finance.sina.com.cn
20. 20斥资80亿港元收购天猫医疗电商业务，阿里健康整合步伐提速finance.sina.com.cn
21. 21针对湖北慢病患者缺药难题 阿里巴巴上线“缺药登记”服务finance.sina.com.cn